Anthropic is pointing its Claude artificial intelligence at a corner of medicine that pharmaceutical companies have long overlooked.
According to a report published by Arkansas Online, the company's new "Claude Science" tool uses AI to tackle rare genetic disorders and tropical diseases — the kinds of conditions that typically get little research attention because there simply aren't enough patients to make them commercially attractive.
The report frames the launch as part of a broader wave, describing how AI firms are increasingly offering up tools to assist pharmaceutical research. In other words, Anthropic is not moving alone: the technology industry is positioning AI as a new engine for drug discovery.
That enthusiasm is showing up in the markets, too. A report from timothysykes.com notes that shares of Recursion Pharmaceuticals (ticker RXRX) steadied after an earnings beat that it says fueled "AI drug hype" — a sign that investors are watching the intersection of artificial intelligence and biotech closely.
The available details on Claude Science remain limited. The sources do not spell out which specific diseases are being targeted first, how the tool works in practice, or which drug developers, if any, are already using it.
Still, the framing matters. Rare and tropical diseases are often called "neglected" precisely because the traditional economics of drug development don't reward companies for pursuing them. If AI can lower the cost and time of early research, it could change that calculus — making it viable to chase treatments for small patient populations that markets have historically passed over.
Why it matters: if AI tools like Claude Science can make researching neglected diseases cheaper and faster, they could open the door to treatments for millions of patients that the drug industry has long deemed not worth the effort.